ARC is a clinical stage company that has a liquid medical device product that can prevent post-surgical internal adhesions. Post-surgical internal adhesions have a big impact on a wide variety of surgeries, including abdominal, gynecological, orthopedic, cosmetic and many more. Impacts can range from frozen knee to chronic pain and even death. ARC's product is dispensed into the surgical site at the end of surgery where it forms a barrier coating to prevent surgical adhesions throughout the entire surgical site. ARC has compelling efficacy in multiple animal species, multiple indications, and superior nonclinical efficacy in head-to-head comparisons with three of the top marketed products. ARC's product has successfully completed a phase 1 study in healthy human volunteers. ARC is presently expanding and completing its preclinical animal (total knee replacement and shoulder cuff) studies and initiate and complete US pivotal trial.